Chen Zhang
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study.
Journal: Frontiers in oncology
Published: September 30, 2025
Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas.
Journal: Annals of hematology
Published: September 05, 2025
Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
Journal: Frontiers in immunology
Published: December 20, 2022
Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma.
Journal: Hematology (Amsterdam, Netherlands)
Published: December 08, 2022
Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma.
Journal: Cancer medicine
Published: August 01, 2022
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
Journal: Bone marrow transplantation
Published: July 29, 2022
Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: January 21, 2022
Angioimmunoblastic T-cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China.
Journal: Leukemia & lymphoma
Published: December 27, 2021
Last Updated: 09/26/2026